Recruiting
Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET)
2025-521330-29-00· Phase 2· Ostfold Hospital Trust· Source
Not yet recruiting
Pilot study on tumor absorbed dose dynamics and pre-treatment dosimetry with [177Lu]-PSMA-I&T in metastatic castration-resistant prostate cancer
2026-526519-12-00· Phase 2· Universitetssykehuset Nord-Norge HF· Source
Recruiting
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
NCT01491815· Phase 4· Karolinska Institutet· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Not yet recruiting
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source
Not yet recruiting
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Aminoglycosides in Early Sepsis
NCT06712641· Phase 4· University Hospital, Akershus· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis
2024-513927-18-00· Phase 2· Oslo University Hospital HF· Source
Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033
2024-520409-38-00· Phase 1· First Tracks Biotherapeutics Inc.· Source
Recruiting
The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients with Peritoneal Metastasis
2024-514879-17-00· Phase 3· Karolinska University Hospital· Source
Recruiting
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig)
2024-517981-40-00· Phase 3· Oslo University Hospital HF· Source
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
Ketamine for Combined Depression and Alcohol Use Disorder
NCT06090422· Phase 1/2· University Hospital of North Norway· Source
Recruiting
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
2023-506998-35-00· Phase 3· Vaestra Goetalandsregionen· Source
Not yet recruiting
Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial
2024-519891-17-00· Phase 2· Universitetssykehuset Nord-Norge HF· Source
Recruiting
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· Phase 3· Uppsala University· Source
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
NCT06653634· Phase 4· Oslo University Hospital· Source
Active, not recruiting
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source
Active, not recruiting
Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor:
The Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)
2023-510184-35-00· Phase 4· Diakonhjemmet Sykehus AS· Source
Active, not recruiting
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· Phase 3· AbbVie· Source
Recruiting
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
2023-506150-21-00· Phase 2· Dr. Falk Pharma GmbH· Source
Recruiting
Atorvastatin in chronic migraine (StainMigChronic)
2022-502177-42-02· Phase 2· St. Olavs Hospital HF· Source
Recruiting
Platform Clinical Study for Conquering Scleroderma
NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777· Phase 3· Eli Lilly and Company· Source
Recruiting
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source
Active, not recruiting
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835· Phase 3· AstraZeneca· Source
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671· Phase 3· AstraZeneca· Source
Active, not recruiting
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
2022-500100-21-01· Phase 2· Oslo University Hospital Hf· Source
Recruiting
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Recruiting
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer
NCT05900206· Phase 2· Karolinska University Hospital· Source
Active, not recruiting
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source
Active, not recruiting
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
NCT05431257· Phase 2· Copenhagen University Hospital, Rigshospitalet· Source
Active, not recruiting
Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
NCT04749667· Phase 1/2· Haukeland University Hospital· Source
Recruiting
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
NCT04588285· Phase 2· Helse Fonna· Source
Showing 50 of 68.